Please assess the completion status of the following clinical trial:

Trial Title: Implant Radiation Therapy or Surgery in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS~Meeting 1 of the following criteria:~* Prostate cancer or suspected prostate cancer confined to the prostate (Decision-Aid Randomization) Clinical stage T1/T2, Due for prostate biopsy or prostate biopsy performed in the last 6 weeks, PSA \< 15 ng/mL~* Histologically confirmed prostate cancer (Treatment Randomization): Clinical stage T1/T2, Re-biopsy after a period of active surveillance is at the discretion of the treating investigator, Must meet 1 of the following risk criteria (PSA test \< 3 months prior to treatment intervention), Low risk: Gleason score ≤ 6 (no tertiary grade 4 or 5) with a PSA of \< 10 ng/mL, intermediate-risk: Gleason score 3 + 4 (no tertiary grade 5) with a PSA \> 10 ng/mL but ≤ 15 ng/mL, Transrectal ultrasound prostate volume ≤ 50 cc~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Life expectancy \> 10 years (Decision-Aid Randomization)~* Satisfactory results from biochemical and hematological profiles that, in the opinion of the investigator, does not preclude patient from the trial~* No unacceptable risk for radical prostatectomy or prostate brachytherapy~* INR \< 1.5~* No severe lower urinary tract symptoms~* No significant obstructive urinary symptoms (i.e., peak urine flow rate \< 10 mL per second, and/or post micturition bladder volume \> 100 mL)~* No other clinical or medical condition that, in the opinion of the investigator, precludes patient from taking part in the trial~* No other active malignancy likely to interfere with subsequent protocol treatment and follow-up~PRIOR CONCURRENT THERAPY:~* No prior pelvic radiotherapy~* No prior abdominoperineal (AP) rectal excision~* No prior standard transurethral resection of prostate~* No prior or concurrent neoadjuvant or adjuvant hormonal treatment, (e.g., LHRH agonists, or anti-androgens or estrogens)~* At least 5 days since prior aspirin or clopidogrel~* No concurrent warfarin

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm Rx1: Radical Prostatectomy (Type: OTHER): Arm Rx1: Radical Prostatectomy
- Arm Rx2: Brachytherapy (Type: OTHER): Arm Rx2: Brachytherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).